SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02869360

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Pilot Study of Positron Emission Tomography (PET) Imaging: Correlations With Advanced Magnetic Resonance Imaging in Multiple Sclerosis

Traditional Magnetic Resonance Imaging (MRI) in Multiple Sclerosis (MS) has enabled clinicians to measure disease activity but there are inherent limitations. Clinical/radiographic dissociation can be seen in some patients and the abnormalities are not specific. This pilot study is an opportunity to determine the relationship between quantitative advanced MRI measures and OCT with PET measurements of microglial activation and myelin health.

NCT02869360 Multiple Sclerosis
MeSH: Multiple Sclerosis Sclerosis


Primary Outcomes

Measure: Whole Brain PBR28 binding

Time: Baseline

Secondary Outcomes

Measure: Lesional PiB binding

Time: Baseline

Measure: Myelin Water Imaging

Time: Baseline

Measure: MR Spectroscopy (Total NAA, NAA/Cr, mI)

Time: Baseline

Measure: Optical Coherence Tomography (RNFL thickness)

Time: Baseline

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 rs6971

- Aged 18 to 60 - High or mixed affinity binder to rs6971 TSPO polymorphism Exclusion Criteria: - Pregnant or breastfeeding - Suffering from an unstable medical condition - Have a neurological or ocular disorder other than MS - Any contra-indications to MRI Inclusion Criteria: - Diagnosed with Multiple Sclerosis according to the 2011 McDonald criteria.

- Aged 18 to 60 - High or mixed affinity binder to rs6971 TSPO polymorphism Exclusion Criteria: - Pregnant or breastfeeding - Suffering from an unstable medical condition - Have a neurological or ocular disorder other than MS - Any contra-indications to MRI Multiple Sclerosis Multiple Sclerosis Sclerosis null



HPO Nodes